AIM To investigate the effects of VSL#3 on tumor formation, and fecal and intestinal mucosal microbiota in azoxymethane/dextran sulfate sodium(AOM/DSS) induced mice model. METHODS C57 BL/6 mice were administered AOM/D...AIM To investigate the effects of VSL#3 on tumor formation, and fecal and intestinal mucosal microbiota in azoxymethane/dextran sulfate sodium(AOM/DSS) induced mice model. METHODS C57 BL/6 mice were administered AOM/DSS to develop the ulcerative colitis(UC) carcinogenesis model. Mice were treated with 5-ASA(75 mg/kg/d), VSL#3(1.5 × 109 CFU/d), or 5-ASA combined with VSL#3 by gavage from the day of AOM injection for three months(five days/week). The tumor load was compared in each group, and tumor necrosis factor(TNF-α) and interleukin(IL)-6 levels were evaluated in colon tissue. The stool and intestinal mucosa samples were collected to analyze the differences in the intestinal microbiota by 16 s rDNA sequencing method.RESULTS VSL#3 significantly reduced the tumor load in AOM/DSS-induced mice model and decreased the level of TNF-α and IL-6 in colon tissue. The model group had a lower level of Lactobacillus and higher level of Oscillibacter and Lachnoclostridium in fecal microbiota than the control group. After the intervention with 5-ASA and VSL#3, Bacillus and Lactococcus were increased, while Lachnoclostridium and Oscillibacter were reduced. 5-ASA combined with VSL#3 increased the Lactobacillus and decreased the Oscillibacter. The intestinal mucosal microbiota analysis showed a lower level of Bifidobacterium and Ruminococcaceae_UCG-014 and higher level of Al oprevotel a in the model group as compared to the control group. After supplementation with VSL#3, Bifidobacterium was increased. 5-ASA combined with VSL#3 increased the level of both Lachnoclostridium and Bifidobacterium. CONCLUSION VSL#3 can prevent UC-associated carcinogenesis in mice, reduce the colonic mucosal inflammation levels, and rebalance the fecal and mucosal intestinal microbiota.展开更多
Probiotics are known as“live microorganisms”and have been proven to have a health effect on hosts at the proper dose.Recently,a kind of probiotic mixture including eight live bacterial strains,VSL#3,has attracted co...Probiotics are known as“live microorganisms”and have been proven to have a health effect on hosts at the proper dose.Recently,a kind of probiotic mixture including eight live bacterial strains,VSL#3,has attracted considerable attention for its combined effect.VSL#3 is the only probiotic considered as a kind of medical food;it mainly participates in the regulation of the intestinal barrier function,including improving tight junction protein function,balancing intestinal microbial composition,regulating immune-related cytokine expression and so on.The objective of this review is to discuss the treatment action and mechanism for the administration of VSL#3 in chronic diseases of animals and humans(including children).We found that VSL#3 has a therapeutic or preventive effect in various systemic diseases per a large number of studies,including digestive systemic diseases(gastrointestinal diseases and hepatic diseases),obesity and diabetes,allergic diseases,nervous systemic diseases,atherosclerosis,bone diseases,and female reproductive systemic diseases.展开更多
This study was undertaken to evaluate the influence of treatment with rifaximin followed by the probiotic VSL#3 versus no treatment on the progression of chronic prostatitis toward chronic microbial prostate-vesiculit...This study was undertaken to evaluate the influence of treatment with rifaximin followed by the probiotic VSL#3 versus no treatment on the progression of chronic prostatitis toward chronic microbial prostate-vesiculitis (PV) or prostate-vesiculo-epididymitis (PVE). A total of 106 selected infertile male patients with bacteriologically cured chronic bacterial prostatitis (CBP) and irritable bowel syndrome (IBS) were randomly prescribed rifaximin (200 mg, 2 tablets bid, for 7 days monthly for 12 months) and probiotic containing multiple strains VSL#3 (450 × 10^9 CFU per day) or no treatment. Ninety-five of them (89.6%) complied with the therapeutic plan and were included in this study. Group A = "6Tx/6-": treatment for the initial 6 and no treatment for the following 6 months (n = 26); Group B = "12Tx": 12 months of treatment (n = 22); Group C = "6-/6Tx": no treatment for the initial 6 months and treatment in the last 6 months (n = 23); Group D = "12-": no treatment (n = 24). The patients of Groups A = "6Tx/6-" and B = "12Tx" had the highest frequency of chronic prostatitis (88.5% and 86.4%, respectively). In contrast, group "12-": patients had the lowest frequency of prostatitis (33.4%). The progression of prostatitis into PV in groups "6Tx/6-" (15.5%) and "6-/6Tx" (13.6%) was lower than that found in the patients of group "12-" (45.8%). Finally, no patient of groups "6Tx/6-" and "6-/6Tx" had PVE, whereas it was diagnosed in 20.8% of group "12-" patients. Long-term treatment with rifaximin and the probiotic VSL#3 is effective in lowering the progression of prostatitis into more complicated forms of male accessory gland infections in infertile patients with bacteriologically cured CBP plus IBS.展开更多
Clinical trials have shown beneficial effects of probiotics on inflammatory bowel diseases (IBD), although the exact mechanism remains unknown. VSL#3, a mixture of 8 probiotic bacteria, has been confirmed to have adju...Clinical trials have shown beneficial effects of probiotics on inflammatory bowel diseases (IBD), although the exact mechanism remains unknown. VSL#3, a mixture of 8 probiotic bacteria, has been confirmed to have adjunctive therapeutic effects on colitis. T follicular helper (Tfh) cells, a new separate subset of CD4+ T helper cells, have been proved to play a vital role in autoimmunity. The present study aimed to identify the beneficial effect of the probiotic mixture VSL#3 on the mouse model of colitis by regulating Tfh cells. Dextran sulfate sodium (DSS) was used to induce chronic colitis in C57BL/6 mice. VSL#3 (3x109 live bacteria) was given to C57BL/6 mice every other day for 60 days by gavage. The disease activity index (DAI), histological activity index (HAI), colon length and myeloperoxidase (MPO) activity were detected. Immunofluorescence was used to visualize the location of Tfh cells. Immunoglobulins, Tfh cells and plasma cells were quantified by enzyme-linked immunosorbent assay (ELISA), flow cytometry, real-time PCR or Western blotting. The results showed that after DSS treatment, the humoral immunity was disordered in C57BL/6 mice, with increased IgM, IgG and IgA levels in colonic mucus and increased Tfh cells in mesenteric lymph nodes (MLN). VSL#3 treatment showed anti-inflammatory effects as evidenced by reduced DAI score, HAI score and MPO activity. IgM, IgG and IgA levels were significantly reduced in colon mucus, and the number of Tfh cells was markedly decreased in MLN after VSL#3 treatment. It was concluded that VSL#3 alleviates DSS-induced colitis by downregulating Tfh cells, and Tfh cells may become a potential therapeutic target for IBD.展开更多
Correction to:Cheng FS,Pan D,Chang B,Jiang M,Sang LX.Probiotic mixture VSL#3:An overview of basic and clinical studies in chronic diseases.World J Clin Cases 2020;8:1361-1384.We are the team of Min Jiang and Li-Xuan S...Correction to:Cheng FS,Pan D,Chang B,Jiang M,Sang LX.Probiotic mixture VSL#3:An overview of basic and clinical studies in chronic diseases.World J Clin Cases 2020;8:1361-1384.We are the team of Min Jiang and Li-Xuan Sang from the First Affiliated Hospital,China Medical University.Now we solemnly declare that the studies mentioned in this article[1]evaluated the probiotic formulation known as VSL#3 before January 31,2016.The probiotic formulation is now commonly referred to as De Simone Formulation.In addition,the product currently known as VSL#3 is not the same as De Simone Formulation.De Simone Formulation is now available as Visbiome in the United States and Vivomixx in Europe.展开更多
目的:探讨益生菌VSL#3对三硝基苯磺酸钠(TNBS)诱导的活动期溃疡性结肠炎(UC)大鼠肠道功能及干扰素(IFN)-γ、白介素12(IL-12)表达的影响。方法:21只8周龄SD大鼠,均分为对照组(A组)、TNBS模型组(B组)及VSL#3治疗组(C组),A组给予0.25 m L...目的:探讨益生菌VSL#3对三硝基苯磺酸钠(TNBS)诱导的活动期溃疡性结肠炎(UC)大鼠肠道功能及干扰素(IFN)-γ、白介素12(IL-12)表达的影响。方法:21只8周龄SD大鼠,均分为对照组(A组)、TNBS模型组(B组)及VSL#3治疗组(C组),A组给予0.25 m L生理盐水灌肠,B、C组给予100 g/L TNBS 0.25 m L灌肠建立UC大鼠模型;造模第2天A、B组给予生理盐水0.25 m L灌胃,C组给予VSL#3溶液0.25 m L灌胃;第8天时处死大鼠,比较各组大鼠结肠黏膜组织形态、病理学评分、疾病活动指数(DAI)评分、髓过氧化物酶(MPO)活性变化和IFN-γ、IL-12免疫阳性细胞的表达。结果:A组肠组织未见溃疡病灶,B组肠组织可见溃疡,充血水肿程度较重,与B组比较,C组较B组溃疡减少、缩小、并有修复;光镜下A组无明显炎症细胞浸润,B组可见大量中性粒细胞及淋巴细胞浸润,黏膜下急性小血管炎症出血和纤维素样坏死,而C组较B组炎性细胞浸润减少;DAI、病理学评分C组较B组均明显下降(P<0.01),MPO活性低于B组而高于A组(P<0.05);B组IFN-γ和IL-12明显高于A组,C组较B组有降低,但仍明显高于A组(P<0.05);UC模型大鼠肠组织IFN-γ与IL-12的IOD值呈显著正相关(r=0.964 0,P<0.01),UC模型大鼠肠组织IFN-γ、IL-12的IOD值与肠组织病理学评分、MPO活性及DAI呈正相关(r=0.875 0、0.881 0及0.767 1,P<0.05;r=0.837 0、0.850 8及0.713 3,P<0.05)。结论:VSL#3辅助治疗对TNBS诱导的UC大鼠有确切疗效,其作用机制可能与益生菌VSL#3通过有效抑制大鼠结肠黏膜IFN-γ、IL-12的表达有关。展开更多
The purpose of this review paper is to update the current and potential future role of probiotics for Clostridium difficile-associated disease (CDAD). Included in this review, is an update on the testing of newer prob...The purpose of this review paper is to update the current and potential future role of probiotics for Clostridium difficile-associated disease (CDAD). Included in this review, is an update on the testing of newer probiotics (e.g. , Bacillus coagulans GBI-30, 6086) in animal models of CDAD. There is a focus on the modulation of signal transduction pathways (i.e. , transcription factors like cAMP response element-binding, activator protein 1, and nuclear factor kappa B), as well as the inhibition of certain kinases (e.g. , p38 mitogen activated protein kinases) by probiotics. Inhibition of signal transduction by probiotics, such as Saccharomyces boulardii , result in multiple effects on intestinal fluid secretion, neutrophil influx into the colon, inflammation, and colonocyte apoptosis that may positively impact CDAD. Recent clinical approaches with probiotics, for the prevention of primary and recurrent CDAD, are also summarized in this review paper. Future directions for the treatment of CDAD by probiotics are also mentioned in this review. In particular, the use of multi-strain probiotic formulations such as Ecologic AAD and VSL #3 may represent a rationale pharmacological approach, particularly as adjunctive therapies for CDAD. Understanding the mechanistic basis of CDAD, and how probiotics interfere at ceratin steps in the pathogenic process, may also present the opportunity to design other multi-strain probiotics that could have a future impact on CDAD.展开更多
基金Supported by the National Natural Science Foundation of China,No.81370500 and No.81770559
文摘AIM To investigate the effects of VSL#3 on tumor formation, and fecal and intestinal mucosal microbiota in azoxymethane/dextran sulfate sodium(AOM/DSS) induced mice model. METHODS C57 BL/6 mice were administered AOM/DSS to develop the ulcerative colitis(UC) carcinogenesis model. Mice were treated with 5-ASA(75 mg/kg/d), VSL#3(1.5 × 109 CFU/d), or 5-ASA combined with VSL#3 by gavage from the day of AOM injection for three months(five days/week). The tumor load was compared in each group, and tumor necrosis factor(TNF-α) and interleukin(IL)-6 levels were evaluated in colon tissue. The stool and intestinal mucosa samples were collected to analyze the differences in the intestinal microbiota by 16 s rDNA sequencing method.RESULTS VSL#3 significantly reduced the tumor load in AOM/DSS-induced mice model and decreased the level of TNF-α and IL-6 in colon tissue. The model group had a lower level of Lactobacillus and higher level of Oscillibacter and Lachnoclostridium in fecal microbiota than the control group. After the intervention with 5-ASA and VSL#3, Bacillus and Lactococcus were increased, while Lachnoclostridium and Oscillibacter were reduced. 5-ASA combined with VSL#3 increased the Lactobacillus and decreased the Oscillibacter. The intestinal mucosal microbiota analysis showed a lower level of Bifidobacterium and Ruminococcaceae_UCG-014 and higher level of Al oprevotel a in the model group as compared to the control group. After supplementation with VSL#3, Bifidobacterium was increased. 5-ASA combined with VSL#3 increased the level of both Lachnoclostridium and Bifidobacterium. CONCLUSION VSL#3 can prevent UC-associated carcinogenesis in mice, reduce the colonic mucosal inflammation levels, and rebalance the fecal and mucosal intestinal microbiota.
基金the Innovative Talent Support Program of the Institution of Higher Learning in Liaoning Province,No.2018-478the Innovative Talents of Science and Technology Support Program of Young and Middle People of Shenyang,No.RC170446.
文摘Probiotics are known as“live microorganisms”and have been proven to have a health effect on hosts at the proper dose.Recently,a kind of probiotic mixture including eight live bacterial strains,VSL#3,has attracted considerable attention for its combined effect.VSL#3 is the only probiotic considered as a kind of medical food;it mainly participates in the regulation of the intestinal barrier function,including improving tight junction protein function,balancing intestinal microbial composition,regulating immune-related cytokine expression and so on.The objective of this review is to discuss the treatment action and mechanism for the administration of VSL#3 in chronic diseases of animals and humans(including children).We found that VSL#3 has a therapeutic or preventive effect in various systemic diseases per a large number of studies,including digestive systemic diseases(gastrointestinal diseases and hepatic diseases),obesity and diabetes,allergic diseases,nervous systemic diseases,atherosclerosis,bone diseases,and female reproductive systemic diseases.
文摘This study was undertaken to evaluate the influence of treatment with rifaximin followed by the probiotic VSL#3 versus no treatment on the progression of chronic prostatitis toward chronic microbial prostate-vesiculitis (PV) or prostate-vesiculo-epididymitis (PVE). A total of 106 selected infertile male patients with bacteriologically cured chronic bacterial prostatitis (CBP) and irritable bowel syndrome (IBS) were randomly prescribed rifaximin (200 mg, 2 tablets bid, for 7 days monthly for 12 months) and probiotic containing multiple strains VSL#3 (450 × 10^9 CFU per day) or no treatment. Ninety-five of them (89.6%) complied with the therapeutic plan and were included in this study. Group A = "6Tx/6-": treatment for the initial 6 and no treatment for the following 6 months (n = 26); Group B = "12Tx": 12 months of treatment (n = 22); Group C = "6-/6Tx": no treatment for the initial 6 months and treatment in the last 6 months (n = 23); Group D = "12-": no treatment (n = 24). The patients of Groups A = "6Tx/6-" and B = "12Tx" had the highest frequency of chronic prostatitis (88.5% and 86.4%, respectively). In contrast, group "12-": patients had the lowest frequency of prostatitis (33.4%). The progression of prostatitis into PV in groups "6Tx/6-" (15.5%) and "6-/6Tx" (13.6%) was lower than that found in the patients of group "12-" (45.8%). Finally, no patient of groups "6Tx/6-" and "6-/6Tx" had PVE, whereas it was diagnosed in 20.8% of group "12-" patients. Long-term treatment with rifaximin and the probiotic VSL#3 is effective in lowering the progression of prostatitis into more complicated forms of male accessory gland infections in infertile patients with bacteriologically cured CBP plus IBS.
基金This study was supported by the National Natural Science Foundation of China (Nos.81800984,81170361).
文摘Clinical trials have shown beneficial effects of probiotics on inflammatory bowel diseases (IBD), although the exact mechanism remains unknown. VSL#3, a mixture of 8 probiotic bacteria, has been confirmed to have adjunctive therapeutic effects on colitis. T follicular helper (Tfh) cells, a new separate subset of CD4+ T helper cells, have been proved to play a vital role in autoimmunity. The present study aimed to identify the beneficial effect of the probiotic mixture VSL#3 on the mouse model of colitis by regulating Tfh cells. Dextran sulfate sodium (DSS) was used to induce chronic colitis in C57BL/6 mice. VSL#3 (3x109 live bacteria) was given to C57BL/6 mice every other day for 60 days by gavage. The disease activity index (DAI), histological activity index (HAI), colon length and myeloperoxidase (MPO) activity were detected. Immunofluorescence was used to visualize the location of Tfh cells. Immunoglobulins, Tfh cells and plasma cells were quantified by enzyme-linked immunosorbent assay (ELISA), flow cytometry, real-time PCR or Western blotting. The results showed that after DSS treatment, the humoral immunity was disordered in C57BL/6 mice, with increased IgM, IgG and IgA levels in colonic mucus and increased Tfh cells in mesenteric lymph nodes (MLN). VSL#3 treatment showed anti-inflammatory effects as evidenced by reduced DAI score, HAI score and MPO activity. IgM, IgG and IgA levels were significantly reduced in colon mucus, and the number of Tfh cells was markedly decreased in MLN after VSL#3 treatment. It was concluded that VSL#3 alleviates DSS-induced colitis by downregulating Tfh cells, and Tfh cells may become a potential therapeutic target for IBD.
文摘Correction to:Cheng FS,Pan D,Chang B,Jiang M,Sang LX.Probiotic mixture VSL#3:An overview of basic and clinical studies in chronic diseases.World J Clin Cases 2020;8:1361-1384.We are the team of Min Jiang and Li-Xuan Sang from the First Affiliated Hospital,China Medical University.Now we solemnly declare that the studies mentioned in this article[1]evaluated the probiotic formulation known as VSL#3 before January 31,2016.The probiotic formulation is now commonly referred to as De Simone Formulation.In addition,the product currently known as VSL#3 is not the same as De Simone Formulation.De Simone Formulation is now available as Visbiome in the United States and Vivomixx in Europe.
文摘目的:探讨益生菌VSL#3对三硝基苯磺酸钠(TNBS)诱导的活动期溃疡性结肠炎(UC)大鼠肠道功能及干扰素(IFN)-γ、白介素12(IL-12)表达的影响。方法:21只8周龄SD大鼠,均分为对照组(A组)、TNBS模型组(B组)及VSL#3治疗组(C组),A组给予0.25 m L生理盐水灌肠,B、C组给予100 g/L TNBS 0.25 m L灌肠建立UC大鼠模型;造模第2天A、B组给予生理盐水0.25 m L灌胃,C组给予VSL#3溶液0.25 m L灌胃;第8天时处死大鼠,比较各组大鼠结肠黏膜组织形态、病理学评分、疾病活动指数(DAI)评分、髓过氧化物酶(MPO)活性变化和IFN-γ、IL-12免疫阳性细胞的表达。结果:A组肠组织未见溃疡病灶,B组肠组织可见溃疡,充血水肿程度较重,与B组比较,C组较B组溃疡减少、缩小、并有修复;光镜下A组无明显炎症细胞浸润,B组可见大量中性粒细胞及淋巴细胞浸润,黏膜下急性小血管炎症出血和纤维素样坏死,而C组较B组炎性细胞浸润减少;DAI、病理学评分C组较B组均明显下降(P<0.01),MPO活性低于B组而高于A组(P<0.05);B组IFN-γ和IL-12明显高于A组,C组较B组有降低,但仍明显高于A组(P<0.05);UC模型大鼠肠组织IFN-γ与IL-12的IOD值呈显著正相关(r=0.964 0,P<0.01),UC模型大鼠肠组织IFN-γ、IL-12的IOD值与肠组织病理学评分、MPO活性及DAI呈正相关(r=0.875 0、0.881 0及0.767 1,P<0.05;r=0.837 0、0.850 8及0.713 3,P<0.05)。结论:VSL#3辅助治疗对TNBS诱导的UC大鼠有确切疗效,其作用机制可能与益生菌VSL#3通过有效抑制大鼠结肠黏膜IFN-γ、IL-12的表达有关。
文摘The purpose of this review paper is to update the current and potential future role of probiotics for Clostridium difficile-associated disease (CDAD). Included in this review, is an update on the testing of newer probiotics (e.g. , Bacillus coagulans GBI-30, 6086) in animal models of CDAD. There is a focus on the modulation of signal transduction pathways (i.e. , transcription factors like cAMP response element-binding, activator protein 1, and nuclear factor kappa B), as well as the inhibition of certain kinases (e.g. , p38 mitogen activated protein kinases) by probiotics. Inhibition of signal transduction by probiotics, such as Saccharomyces boulardii , result in multiple effects on intestinal fluid secretion, neutrophil influx into the colon, inflammation, and colonocyte apoptosis that may positively impact CDAD. Recent clinical approaches with probiotics, for the prevention of primary and recurrent CDAD, are also summarized in this review paper. Future directions for the treatment of CDAD by probiotics are also mentioned in this review. In particular, the use of multi-strain probiotic formulations such as Ecologic AAD and VSL #3 may represent a rationale pharmacological approach, particularly as adjunctive therapies for CDAD. Understanding the mechanistic basis of CDAD, and how probiotics interfere at ceratin steps in the pathogenic process, may also present the opportunity to design other multi-strain probiotics that could have a future impact on CDAD.